Abstract
The prevalence of smoking among hospitalised COVID-19 patients is low. COVID-19 manifestations could be linked to impairment of the cholinergic anti-inflammatory pathway. Nicotinic cholinergic agonists should be examined as potential therapeutic options. https://bit.ly/2zfUZ1S
MeSH terms
-
Betacoronavirus
-
COVID-19
-
Cholinergic Agents
-
Coronavirus Infections*
-
Humans
-
Nicotine*
-
Pandemics*
-
Pneumonia, Viral*
-
Pulmonary Disease, Chronic Obstructive*
-
SARS-CoV-2
-
Smokers
Substances
-
Cholinergic Agents
-
Nicotine